Business
WELL Health Subsidiary WELLSTAR Provides Corporate Update Reflecting Improved Guidance and a Strong Acquisition Pipeline
WELLSTAR continues to demonstrate strong growth and business momentum through its sustained organ...
About this update from Well Health Technologies Corp.
[{"type":"text","content":"WELL Health Subsidiary WELLSTAR Provides Corporate Update Reflecting Improved Guidance and a Strong Acquisition Pipeline\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }\n \n\n\n\n\n WELLSTAR continues to demonstrate strong growth and business momentum through its sustained organic growth and strong acquisition pipeline. The business is ahead of its internal expectations and has updated its guidance to $74 million\n \n (1)\n \n in total revenue and $22 million\n \n (1)\n \n in Adjusted EBITDA\n \n (2)\n \n for fiscal 2025, ending the year with total ARR of $62 million and an exit ARR\n \n (3)\n \n of approximately $80 million.\n \n\n WELLSTAR has executed three LOIs for acquisitions that will drive approximately $15 million in ARR, $16 million in revenues and over $5 million in Adjusted EBITDA on an annualized basis.\n \n\n WELLSTAR’s recently launched Nexus AI™ solution has generated significant early momentum. As a pre-qualified vendor for Canada Health Infoway’s AI Scribe Program, eligible primary care clinicians can now receive a fully-funded Nexus AI license for 12 months.\n \n\n\n\n\n WELL Health Technologies Corp. (TSX: WELL) (“\n \n WELL\n \n ” or the “\n \n Company\n \n ”), a company focused on positively impacting health outcomes by leveraging technology to empower healthcare providers and their patients, is pleased to provide a corporate update highlighting continued momentum across its majority-owned subsidiary, WELLSTAR Technologies Corp. (“\n \n WELLSTAR\n \n ”). WELLSTAR is tracking ahead of internal expectations, supported by robust organic growth, a strong acquisition pipeline, and accelerating adoption of its Nexus AI solution.\n \n\n WELLSTAR continues to demonstrate strong growth and execution, fueled by accelerating demand for its digital health solutions and steady progress across its platform. The business is tracking ahead of internal expectations and has updated its guidance for fiscal 2025 to over $74 million\n \n (1)\n \n in revenue and $22 million\n \n (1)\n \n in Adjusted EBITDA\n \n (2)\n \n . WELLSTAR is also expected to end the year with total annual recurring revenue (ARR) of approximately $62 million and an exit ARR\n \n (3)\n \n of...